Peethaambaran Kunnathoor, Chennai Saturday, May 17, 2025, 08:00 Hrs [IST] ...

Top Companies Covered In This Ketorolac Market Report: Allergan plc, Deepcare Health Pvt Ltd, Cadila Healthcare Limited, Intas Pharmaceuticals Limited, Ranbaxy Laboratories Limited, Omeros ...

Multibagger stock: Pharma company Sudarshan Pharma Industries share price will remain in focus in Monday's trading session after the company reported its half yearly and FY25 financial ...

The Pharma stocks are seeing big cuts in early trade. The Nifty Pharma Index is down over 1% and the BSE Healthcare Index too remains under pressure. Some of the big Nifty losers include the likes ...

A fresh threat by US president Donald Trump on Monday that sector-specific tariffs on pharmaceuticals could be announced in the next two weeks has hammered the stocks of Indian drug-makers on ...

(Reuters) -Bain Capital is in talks to buy contract drug manufacturer PCI Pharma Services at a valuation of $10 billion, Bloomberg News reported on Friday, citing people familiar with the matter.

Shares of Japanese drugmaker Shionogi & Co. dropped the most in almost a month after the Nikkei newspaper reported the company will buy Torii Pharmaceutical Co. for about ¥150 billion ($1 billion).

Mira Pharmaceuticals, Inc.’s (NASDAQ:MIRA) Board of Directors unanimously approved on Thursday the planned acquisition of SKNY Pharmaceuticals, Inc., following the completion of independent ...

NEW YORK, May 16, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has successfully closed the acquisition of its external manager, RP Management, LLC ("RP Management ...

as he performs live in Indore this weekend. You can experience powerful beats, raw energy, and a night you won’t forget. Don’t miss the chance to catch him live on stage workshop is all about ...

Indore (Madhya Pradesh): An employment fair ... IT, retail, e-commerce, BPO consultancy, pharma, fintech, sales, marketing, accounting, real estate and finance companies will recruit workers ...

At the time of the complaint, Incyte allegedly owed Novartis $27.5 million, plus interest, in missed royalty payments, according to the Swiss pharma giant. Incyte crosses $1B in quarterly revenue ...